What is the recommended first‑line filler treatment for a patient with smoker’s lines, including product choice, injection technique, volume, and pre‑procedure smoking cessation advice?

Hyaluronic Acid Fillers for Smoker's Lines

For perioral rhytides (smoker's lines), inject small-particle hyaluronic acid filler (20 mg/mL with lidocaine) into the superficial dermis using serial puncture or linear threading technique, with volumes of 0.1–0.3 mL per line, and strongly advise smoking cessation before treatment to optimize outcomes and reduce complications.

Pre-Procedure Smoking Cessation Counseling

Mandatory Cessation Advice

• Provide unambiguous, nonjudgmental, patient-specific advice regarding the importance of cessation to all smokers before performing aesthetic procedures, as smoking impairs wound healing and increases complication risk 1.
• Offer assistance with smoking cessation initiation—either directly or through referral to appropriate resources 1.
• Document the patient's smoking status in the medical record before any aesthetic procedure 1.

First-Line Pharmacotherapy for Cessation

• Recommend combination nicotine replacement therapy (21 mg/24-hour patch plus short-acting NRT such as 2–4 mg gum) as first-line treatment, which achieves approximately 36.5% abstinence at 6 months versus 23.4% for patch alone 2, 3.
• Alternative first-line option: varenicline 1 mg twice daily for 12 weeks, which achieves approximately 28% abstinence versus 12% with placebo 2, 3.
• Combine pharmacotherapy with at least 4 behavioral counseling sessions totaling 91–300 minutes of contact for optimal results 2, 3.

Timing Considerations

• Ideally, patients should achieve smoking cessation before filler treatment to maximize tissue health and minimize adverse events, though the evidence does not specify an exact pre-treatment cessation period 1.
• If the patient cannot quit before treatment, counsel them about increased risks of bruising, swelling, and suboptimal aesthetic outcomes 1.

Product Selection for Smoker's Lines

Recommended Filler Type

• Small-particle hyaluronic acid 20 mg/mL with lidocaine 0.3% (e.g., Restylane® Silk) is specifically indicated for dermal implantation for correction of perioral rhytides 4.
• The smaller particle size and rheological properties make this formulation well-suited for very fine perioral lines 4.
• Alternative products include Hylacross®-based fillers (e.g., HA E Touch or HA E Classic) for upper lip lines, which demonstrated sustained improvement with around 1-grade improvement persisting at 6 months 5.

Product Characteristics

• Small-particle HA fillers show excellent dermal integration and handling properties for superficial injection 4, 6.
• These products are safe and well-tolerated, with injection site responses generally mild or moderate in severity and resolving within 2 weeks 5, 7.

Injection Technique

Anatomical Approach

• Inject into the superficial dermis for correction of fine perioral rhytides 4.
• Use either serial puncture technique or linear threading technique depending on the pattern and depth of the lines 4.
• A comprehensive understanding of lower face anatomical features and injection site techniques is foundational for safe and effective outcomes 4.

Volume Guidelines

• Use 0.1–0.3 mL per individual line, with total volumes typically ranging from 0.5–1.0 mL for the entire perioral region depending on severity 5, 4.
• Avoid over-correction; aim for subtle enhancement that appears natural 4, 6.

Injection Protocol

• Consider a touch-up injection 3 weeks after initial treatment to achieve optimal correction 5.
• Optimal correction is defined as results obtained 3 weeks after the last injection 5.

Expected Outcomes and Duration

Efficacy Data

• Approximately 1-grade improvement on wrinkle assessment scales (Lemperle Rating Scales) persists at 6 months after treatment 5.
• 3-D volume analyses confirm that 62.7–71.4% of volumes obtained at week 3 are maintained after 6 months 5.
• Patient satisfaction rates range from 80–95% for perioral enhancement procedures 5.

Safety Profile

• The most common adverse events are injection site mass (19.4%) and bruising (12.5%) 7.
• All injection site responses are generally mild or moderate, resolve within 2 weeks, and are consistent with expected HA filler treatment 5, 7.
• No serious adverse events have been reported in clinical studies of perioral HA filler treatment 5, 6.

Post-Treatment Care

Patient Instructions

• Provide post-treatment advice for optimal results, including avoidance of excessive facial movement and pressure on treated areas for 24–48 hours 6.
• Counsel patients about expected injection site responses (swelling, bruising, tenderness) and their typical resolution timeline 7.

Follow-Up Schedule

• Evaluate results at 3 weeks post-treatment to assess need for touch-up injection 5.
• Schedule follow-up at 6 months to assess durability of correction and discuss maintenance treatment 5.

Common Pitfalls and How to Avoid Them

Technical Errors

• Injecting too deeply (into subcutaneous tissue rather than dermis) reduces efficacy for fine lines; maintain superficial placement 4.
• Over-correction creates an unnatural appearance; aim for subtle, gradual improvement 4, 6.
• Inadequate volume leads to suboptimal correction; use sufficient product to achieve visible improvement 5.

Patient Selection Issues

• Failing to address active smoking before treatment increases complication risk and reduces aesthetic outcomes 1.
• Not documenting smoking status represents a missed opportunity for secondary prevention counseling 1.
• Ignoring patient expectations can lead to dissatisfaction; ensure realistic goals are established before treatment 8.